Sign In
Last checked at 
11 May 2015 07:00
For immediate release | 11 May 2015 |
Futura Medical plc
("Futura" or "the Company")
Block Listing Update
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, since the last update in November 2014, there have been no changes to the numbers of shares block listed in respect of the Company's two option plans. All ordinary shares of 0.2 pence each.
The table below provides further detail.
Name of company: | Futura Medical plc | |
Name of scheme: | Unapproved Share Option Scheme ("USOS")EMI Share Option Scheme ("EMI")
| |
Period of return: | From: | 11 November 2014 |
To: | 11 May 2015
| |
Number and class of securities not issued under the scheme(s) | USOS: | 1,786,435 |
EMI: | 1,828,306 | |
Total: | 3,614,741
| |
Number of securities issued under the scheme(s) during the period
Number of securities lapsed under the scheme(s) during the period | USOS: | Nil |
EMI:
USOS: EMI: Total: | Nil
345,835 434,165 780,000
| |
Balance under the scheme(s) of securities not yet issued at the end of the period | USOS: | 1,440,600 |
EMI: | 1,394,141 | |
Total: | 2,834,741
| |
Number and class of securities originally admitted and the date of admission | USOS: | 814,424 on 25 May 2011 and 1,202,280 on 8 October 2013 |
Total: | 2,016,704 Total | |
EMI: | 1,520,576 on 25 May 2011 and 1,467,720 on 8 October 2013 | |
Total: | 2,988,296 Total | |
Total: | 5,005,000
| |
Name of contact: | Derek Martin, Chief Financial Officer | |
Telephone number of contact: | +44 (0) 1483 685 670 | |
For further information please contact:
Futura Medical plc | |
James Barder, Chief Executive + 44 (0) 1483 685 670 james.barder@futuramedical.com www.futuramedical.com |
|
N+1 Singer (Nominated Adviser and Broker)Aubrey Powell / Thomas Smale+44 (0) 20 7496 3000 | |
For media enquiries please contact:
Buchanan Mark Court / Sophie Cowles / Stephanie Watson + 44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Follow the stocks
